What is the appropriate management of acute kidney injury in a patient with hepatic failure?

Management of Acute Kidney Injury in Hepatic Failure

In patients with cirrhosis and AKI, immediately discontinue all diuretics and nephrotoxic drugs, administer albumin 1 g/kg/day (maximum 100 g) for 2 consecutive days, and if AKI persists at stage 2 or 3 after this albumin challenge, initiate vasoconstrictor therapy with terlipressin plus albumin for hepatorenal syndrome-AKI. 1

Initial Diagnostic Assessment and Staging

Define AKI Using Current Criteria

• Stage 1 AKI: Serum creatinine increase ≥0.3 mg/dL within 48 hours OR 1.5-1.9× baseline OR urine output <0.5 mL/kg/h for 6 hours 1, 2
• Stage 2 AKI: Serum creatinine 2.0-2.9× baseline 1
• Stage 3 AKI: Serum creatinine ≥3.0× baseline OR ≥4.0 mg/dL with acute rise ≥0.3 mg/dL OR initiation of RRT 1
• Use the most recent serum creatinine within the prior 3 months as baseline; do not calculate baseline using MDRD equation in cirrhotic patients as it is markedly inaccurate 2

Identify the Etiology

• Perform urinalysis with microscopy immediately to distinguish prerenal/HRS-AKI (bland sediment) from acute tubular necrosis (muddy brown casts) or other structural causes 2
• Approximately 50% of AKI in cirrhosis is prerenal, 35% is acute tubular necrosis, and the remainder is HRS-AKI 2
• Search aggressively for infection: obtain blood cultures, urine cultures, chest radiography, and perform diagnostic paracentesis in all patients with ascites to exclude spontaneous bacterial peritonitis 2, 3
• Review all medications and recent exposures to nephrotoxins (NSAIDs, aminoglycosides, contrast agents, ACE inhibitors) 1, 2

Immediate Management: All Stages of AKI

Medication Withdrawal (First Priority)

• Stop all diuretics immediately, regardless of AKI stage 1, 2
• Discontinue all nephrotoxic agents: NSAIDs, ACE inhibitors, ARBs, aminoglycosides, and vasodilators 1, 2
• This step alone may reverse stage 1 AKI within 48 hours 2

Volume Assessment and Expansion

• Assess for hypovolemia by examining orthostatic vital signs, mucous membranes, jugular venous pressure, and recent fluid losses (GI bleeding, diarrhea, excessive diuresis) 2
• If hypovolemia is present, administer albumin 20-25% at 1 g/kg/day (maximum 100 g) for 2 consecutive days 1, 2
• Albumin is superior to crystalloids in cirrhosis because crystalloids accumulate preferentially in ascites and edema rather than expanding central circulating volume 2
• Monitor closely for pulmonary edema with albumin infusion 1

Infection Control

• Initiate broad-spectrum antibiotics immediately when infection is diagnosed or strongly suspected 2
• In spontaneous bacterial peritonitis with elevated creatinine, give albumin 1.5 g/kg within 6 hours of diagnosis, followed by 1 g/kg on day 3 2

Stage-Specific Management Algorithm

Stage 1 AKI Management

• After diuretic withdrawal and volume expansion, monitor serum creatinine every 2-4 days inpatient 2
• If creatinine returns to within 0.3 mg/dL of baseline within 48 hours, continue close monitoring and follow for 6 months outpatient 2
• If AKI progresses to stage 2 or 3, escalate to stage 2/3 protocol 2

Stage 2 and Stage 3 AKI Management

• Ensure diuretics are stopped and albumin 1 g/kg/day (max 100 g) has been given for 2 days 1
• Reassess after 48 hours: if serum creatinine remains >2× baseline or continues rising, evaluate for HRS-AKI using diagnostic criteria 1
• If criteria for HRS-AKI are not met (e.g., acute tubular necrosis is present), continue supportive care and close monitoring 3

Hepatorenal Syndrome-AKI: Diagnosis and Treatment

Diagnostic Criteria (All Must Be Present)

1. Cirrhosis with ascites 1
2. Stage 2 or 3 AKI 1
3. No improvement after 2 days of diuretic withdrawal AND albumin 1 g/kg/day 1
4. Absence of shock 1
5. No current or recent nephrotoxic drug exposure 1
6. No structural kidney injury: proteinuria <500 mg/day, hematuria <50 RBCs/hpf, normal renal ultrasound 1

Vasoconstrictor Therapy for HRS-AKI

First-Line: Terlipressin Plus Albumin

• Terlipressin 1-2 mg IV every 6 hours for up to 14 days, combined with albumin 1
• Discontinue if no response by day 3 or 4 1
• Do not use terlipressin if serum creatinine ≥5 mg/dL or oxygen saturation <90% 1
• Predictors of response: baseline bilirubin <10 mg/dL, baseline creatinine <5 mg/dL, sustained MAP increase of 5-10 mm Hg 1
• Monitor for ischemic complications (angina, digital ischemia, intestinal ischemia) and respiratory failure, especially in patients with baseline organ failure 1
• Start at the lowest dose and titrate gradually to minimize ischemic side effects 1

Second-Line: Norepinephrine Plus Albumin (ICU Setting)

• Norepinephrine 0.5 mg/h continuous IV infusion, increase by 0.5 mg/h every 4 hours to maximum 3 mg/h 1
• Goal: increase MAP by ≥10 mm Hg and/or urine output >50 mL/h for at least 4 hours 1
• Norepinephrine improves renal function in 39-70% of patients, similar to terlipressin 1
• Requires ICU monitoring due to risk of cardiac arrhythmias and ischemic complications 1
• In acute-on-chronic liver failure (bilirubin >5 mg/dL, INR >1.5, hepatic encephalopathy or ascites within 4 weeks), terlipressin is superior to norepinephrine 1

Third-Line: Midodrine Plus Octreotide (When Terlipressin Unavailable)

• Midodrine 7.5 mg PO, titrate to 12.5 mg three times daily 1
• Octreotide 100 mcg subcutaneously, titrate to 200 mcg three times daily 1
• This combination is inferior to terlipressin but may achieve HRS reversal slowly 1
• Generally well tolerated; monitor for headaches, blurred vision, palpitations (midodrine) and nausea, abdominal pain (octreotide) 1

Renal Replacement Therapy Indications

When to Initiate RRT

• RRT should be used in HRS-AKI ONLY as a bridge to liver transplantation in current or potential transplant candidates 1
• RRT is appropriate for AKI secondary to acute tubular necrosis in transplant candidates 1
• RRT is indicated for volume overload, severe electrolyte derangements (hyperkalemia), or uremia 1
• Do not use RRT in HRS-AKI patients who are not liver transplant candidates 1
• Continuous RRT is preferred over intermittent RRT due to lower fluid shifts and reduced hemodynamic instability 1

Prognosis with RRT

• Mortality is 59% in patients requiring >7 days of RRT 1
• Two-thirds of HRS-AKI patients on RRT pretransplant recover renal function after liver transplant 1
• Cutoff duration for predicting renal recovery is approximately 14 days; each additional day on dialysis increases risk of renal nonrecovery by 3.6-6% 1

Liver Transplantation Considerations

Transplantation as Definitive Treatment

• Liver transplantation is the most effective treatment for HRS-AKI 1
• Pharmacotherapy for HRS-AKI before liver transplant may improve post-transplant outcomes 1
• Do not withhold vasoconstrictor therapy despite concerns about lowering MELD-Na score; benefits of treatment outweigh risks of decreased transplant priority 1

Simultaneous Liver-Kidney Transplantation

• Consider simultaneous liver-kidney transplant based on updated OPTN criteria: patient on dialysis OR measured/calculated GFR ≤25 mL/min for 6 consecutive weeks 1
• Patients can be registered for kidney transplant alone with high priority if persistent renal dysfunction (ESRD or GFR <20 mL/min) occurs after liver transplant 1

Critical Pitfalls to Avoid

• Do not use transjugular intrahepatic portosystemic shunts (TIPS) as specific treatment for HRS-AKI 1
• Do not rely on calculated GFR formulas (MDRD, CKD-EPI) in cirrhotic patients; they substantially overestimate renal function 2
• Do not delay albumin challenge in stage 2/3 AKI; the 2-day trial is essential to differentiate HRS-AKI from other causes 3
• Do not continue diuretics "at low doses" during AKI; even minimal doses worsen renal function 2
• Do not assume all AKI in cirrhosis is HRS-AKI; acute tubular necrosis is present in 35% of cases and requires different management 2, 3
• Monitor fluid status meticulously during albumin therapy to prevent pulmonary edema 1